Voclosporin could turn out to be the next standard of care for lupus nephritis. That's a big deal from a commercial standpoint because this market is expected to grow by leaps and bounds over the next few years. Moreover, several big pharmas and blue chip biotechs have a keen interest in lupus medications in general. So there's a good chance that Aurinia may fetch a worthwhile buyout offer in the not-so-distant future.